The voluntary buyout offer is the clearest sign yet that Microsoft will trim headcount even as it accelerates AI infrastructure spending.

CEO Minami Maeda is running Phase 3 trials and targeting a 2028 FDA submission as photoimmunotherapy moves from Japanese clinics toward the world's largest market.

The rocket giant is building an AI chip rental empire, and its founder just warned that weaker players won't survive the compute arms race.

Parts shortages are turning young aircraft into donor planes, upending fleet economics for airlines and lessors.

Flanagan and King extend the story beyond the prom after a 105-country No. 1 debut.

The social media giant's ad engine and AI bet absorbed a massive teen-safety settlement and a new $25B privacy fine, keeping growth on track.

Musk's probability call on catching both stages with the tower, and what it means for rapid reusability.

A 10,000-person study finds standard antidepressants often fail these patients, but melatonin and morning sunlight may hit the real root cause.

The Hunger Games and John Wick owner is now in play, with activist pressure mounting and a $3.6 billion market cap on the table.

If the claim holds up, personalized phage therapy could become a new frontline weapon against antibiotic resistance - but proof is far from final.

The alleged victim's account sharpens the reputational and legal stakes for Brand, his platforms, and any business tied to a public figure under criminal scrutiny.

A new AI tool estimates biological age from a single patient selfie, giving oncologists a fast, non-invasive survival signal - and raising questions about how far facial analysis should go.